ClinicalTrials.gg
Not yet recruitingNCT06299982Updated Mar 8, 2024

An Phase III Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With PsO

A Phase 3 interventional study of 608 Q2W and 608 Q4W in Plaque Psoriasis Patients, sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-08.

Sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (part of 3SBio Inc.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 9 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
750
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to examin the efficacy and safety of the study drug recombinant anti-IL-17A humanized monoclonal antibody in Chinese participants with moderate-to-severe plaque psoriasis.

02

Conditions studied

  • Plaque Psoriasis Patients

Browse trials for

03

In context

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

This study's planned enrollment of 750 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.

Browse Psoriasis studies →

Lead sponsor

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. is the lead sponsor of 59 studies on the registry; 22 are open to participants now.

First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years old, both male and female.
  • Diagnosis of plaque psoriasis according to the Chinese Guideline for the Diagnosis and Treatment of Psoriasis (2018).

Exclusion criteria

Exclusion Criteria:

  • Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and/or guttate psoriasis) .
  • Other inflammatory diseases.
  • Active diseases.
  • Pregnant or lactating women.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
750 participants (estimated)

Study arms

  • Experimental
    608 160 mg W0+80 mg Q2W

    Participants will receive starting dose of 160 milligrams (mg) 608 at week 0 followed by 80mg 608 once every two weeks (Q2W) by subcutaneous injection for 12 weeks.

    Drug: 608 Q2W

  • Experimental
    608 160 mg Q4W

    Participants will receive 160 milligrams 608 once every four weeks (Q4W) by subcutaneous injection for 12 weeks.

    Drug: 608 Q4W

Interventions

  • Drug608 Q2W

    608 160 mg at week 0 + 80 mg Q2W (5 cycles)

  • Drug608 Q4W

    608 160 mg Q4W (3 cycles)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75)

    Time frame: At Week 12

  2. Percentage of Participants With a Static Physician Global Assessment (sPGA) Score of Clear (0) or Minimal (1) With at Least a 2 Point Improvement

    Time frame: At Week 12

Secondary outcomes

  1. Percentage of Participants Achieving a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90)

    Time frame: At Week 12

  2. Percentage of Participants Achieving a ≥100% Improvement in Psoriasis Area and Severity Index (PASI 100)

    Time frame: At Week 12

  3. Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of Clear (0)

    Time frame: At Week 12

  4. Adverse events (AE)

    Time frame: 20 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2024; primary completion for Jan 2025, 8 months later.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's planned 8 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2024
First posted
Mar 8, 2024
StartEst.
May 15, 2024
Primary completionEst.
Jan 30, 2025
CompletionEst.
Mar 20, 2025
Last update
Mar 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06299982
Responsible party
Sponsor
First posted
Mar 8, 2024
Start date
May 15, 2024 (estimated)
Primary completion
Jan 30, 2025 (estimated)
Completion
Mar 20, 2025 (estimated)
Last update
Mar 8, 2024

Study contacts

Qinghong Zhou
Contact
zhouqinghong@3sbio.com
+86 18911301578

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion